Corporate Africa · Funding signal
New York-listed Regeneron secures $270 million US Ebola order as African outbreak approaches 10,000 infections
New York-listed Regeneron secures $270 million US Ebola order as African outbreak approaches 10,000 infections — the desk wire, 28 October 2026. US pharmaceutical company Regeneron has secured an additional $270 million order from the US government for its approved Ebola treatment as a separate strain of the virus spreads across Africa.
Updated 28 October 2026 · First published 28 October 2026
Read the original at the desk wire ↗Follow the desk →